The NIH Blueprint Neurotherapeutics Program provides academic and industry researchers with support, taking small molecule drug candidates from the medicinal chemistry to Phase I clinical trials stages. The program is focused on any disorder involving the nervous system: including neurological diseases, psychiatric disorders, age-related dementias, developmental disorders, visual, hearing loss, chronic pain, alcohol dependence and drug addiction.
The program is described at http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm. In the program the principal investigator receives in-kind R&D services provided through NIH contracts, from CROs and consultants that typically serve the biopharmaceutical industry. Capabilities are provided for medicinal chemistry, pharmacology, in vitro and in vivo ADMET, data management, formulations development, GMP scale-up synthesis, and Phase I trials; and direct funding to partially cover the costs of assay and efficacy studies. Details of the entry criteria are described in the NIH announcement at http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-13-003.html.
Unique features of the BPN translational program are that all inventions arising in the partnership are assigned to the Principal Investigator up-front, and foreign organizations are eligible to apply.
We request that a Letter of Intent is sent as soon as possible so that we can plan for the numbers and types of applications, but it is not necessary. It is easy to write and just needs to include:
Please email this to Dr. Rebecca Farkas, Program Director for Blueprint Neurotherapeutics Program at firstname.lastname@example.org. For additional information please contact Dr. Eric Nelson at email@example.com prior to submission.
Last updated September 26, 2012